The estimated Net Worth of Kimberly Gentile is at least $3.16 Milion dollars as of 6 January 2022. Ms. Gentile owns over 3,750 units of Biohaven Ltd stock worth over $480,541 and over the last 7 years she sold BHVN stock worth over $0. In addition, she makes $2,680,490 as Senior Vice President - Clinical Operations at Biohaven Ltd.
Sign up
Ms. Gentile BHVN stock SEC Form 4 insiders trading
Kimberly has made over 17 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 3,750 units of BHVN stock worth $133,950 on 6 January 2022.
The largest trade she's ever made was exercising 25,000 units of Biohaven Ltd stock on 20 November 2019 worth over $15,250. On average, Kimberly trades about 5,473 units every 64 days since 2017. As of 6 January 2022 she still owns at least 13,453 units of Biohaven Ltd stock.
You can see the complete history of Ms. Gentile stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kimberly Gentile biography
Kimberly A. Gentile serves as Senior Vice President - Clinical Operations of the Company. Ms. Gentile has served as our senior vice president, clinical operations since February 2014. Before coming to Biohaven, Ms. Gentile served as associate director, project manager, global clinical operations at BMS from 2000 to February 2014. Prior to this, she was a senior clinical trial manager at SCIREX Corporation from 1996 to June 2000. Ms. Gentile received her B.S. in Psychology from Salem State University.
What is the salary of Kimberly Gentile?
As the Senior Vice President - Clinical Operations of Biohaven Ltd, the total compensation of Kimberly Gentile at Biohaven Ltd is $2,680,490. There are 3 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Kimberly Gentile?
Kimberly Gentile is 54, she's been the Senior Vice President - Clinical Operations of Biohaven Ltd since 2014. There are 12 older and 3 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's Kimberly Gentile's mailing address?
Kimberly's mailing address filed with the SEC is C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs a Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Ms. Gentile stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer